Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience
Cytometry Part B: Clinical Cytometry · 2023
DOI: 10.1002/cyto.b.22139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2023. Verfasst von Arun Kumar Arunachalam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: The Wellcome Trust DBT India Alliance.
Abstract (Originalsprache)
The assessment of measurable residual disease (MRD) has emerged as a powerful prognostic tool for both pediatric and adult acute lymphoblastic leukemia (ALL). This retrospective study aimed to evaluate the prognostic relevance of the end of induction MRD in B‐cell acute lymphoblastic leukemia (B ALL) patients. The study included 481 patients who underwent treatment for B ALL between August 2012 and March 2019 and had their MRD at the end of induction assessed by flow cytometry. Baseline demographic characteristics were collected from the patient's clinical records. Event free survival (EFS) and relapse free survival (RFS) were calculated using Kaplan–Meier analysis and survival estimates were compared using the log‐rank test. End of induction MRD and baseline karyotype were the strongest predictors of EFS and RFS on multivariate analysis. The EFS was inversely related to the MRD value and the outcomes were similar in patients without morphological remission at the end of induction and patients in remission with MRD ≥1.0%. Even within the subgroups of ALL based on age, karyotype, BCR::ABL1 translocation and the treatment protocol, end of induction MRD positive patients had poor outcomes compared to patients who were MRD negative. The study outcome would help draft end of induction MRD‐based treatment guidelines for the management of B ALL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Christian Medical College, Vellore, India.
- Department of Biostatistics, Christian Medical College, Vellore, India.
ORCID-Profile: Arun Kumar Arunachalam
Förderung
- The Wellcome Trust DBT India Alliance
Zitieren
APA
Arunachalam, A. K., Selvarajan, S., Mani, T., Janet, N. B., Maddali, M., Lionel, S. A., Kulkarni, U., Korula, A., Aboobacker, F. N., Abraham, A., George, B., Balasubramanian, P., & Mathews, V. (2023). Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22139
Vancouver
Arunachalam AK, Selvarajan S, Mani T, Janet NB, Maddali M, Lionel SA, et al. Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience. Cytometry Part B: Clinical Cytometry. 2023. doi:10.1002/cyto.b.22139
BibTeX
@article{Arunachalam2023,
author = {Arunachalam, Arun Kumar and Selvarajan, Sushil and Mani, Thenmozhi and Janet, Nancy Beryl and Maddali, Madhavi and Lionel, Sharon Anbumalar and Kulkarni, Uday and Korula, Anu and Aboobacker, Fouzia N and Abraham, Aby and George, Biju and Balasubramanian, Poonkuzhali and Mathews, Vikram},
title = {Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2023},
doi = {10.1002/cyto.b.22139}
}
EUVIMED